Cargando…

Serological Diagnosis of Liver Metastasis in Patients with Breast Cancer

OBJECTIVE: To diagnose and explore the serological diagnostic factors for liver metastasis in patients with breast cancer before symptoms occur. METHODS: A total of 430 female in-patients with breast cancer of stages 0 to IIIC who came to Tianjin Medical University Cancer Institute and Hospital from...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Rui, Wang, Li-ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643646/
https://www.ncbi.nlm.nih.gov/pubmed/23691457
http://dx.doi.org/10.3969/j.issn.2095-3941.2012.01.011
_version_ 1782268347967078400
author Cao, Rui
Wang, Li-ping
author_facet Cao, Rui
Wang, Li-ping
author_sort Cao, Rui
collection PubMed
description OBJECTIVE: To diagnose and explore the serological diagnostic factors for liver metastasis in patients with breast cancer before symptoms occur. METHODS: A total of 430 female in-patients with breast cancer of stages 0 to IIIC who came to Tianjin Medical University Cancer Institute and Hospital from January 2003 to January 2004 were studied and followed up until May 2011. Serum levels of biochemical markers for tumor and liver were measured at the time of diagnosis. RESULTS: Liver metastasis was more likely to occur in patients with stage III cancer or c-erbB-2-positive expression. Alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase (GGT), alkaline phosphatase, lactate dehydrogenase (LDH), and carbohydrate antigen 153 (CA153) levels were significantly higher in patients with liver metastasis than those without liver metastasis. Diagnostic indices of LDH, GGT, and CA153 were 174 U/L, 32 U/L, and 26.48 µg/L, respectively. The areas under the curves of LDH, GGT, and CEA were 0.795, 0.784, and 0.661, respectively, and sensitivities of parallel tests for LDH and CA153 and for GGT and CA153 were 88.6% and 85.7%, respectively. The specificity of serial tests for both pairs of enzymes was 97.7%. CONCLUSIONS: The sensitivity and specificity of combined tumor and biochemical markers could be used as indicators during screening for breast-liver metastasis.
format Online
Article
Text
id pubmed-3643646
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Chinese Anti-Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-36436462013-05-20 Serological Diagnosis of Liver Metastasis in Patients with Breast Cancer Cao, Rui Wang, Li-ping Cancer Biol Med Original Article OBJECTIVE: To diagnose and explore the serological diagnostic factors for liver metastasis in patients with breast cancer before symptoms occur. METHODS: A total of 430 female in-patients with breast cancer of stages 0 to IIIC who came to Tianjin Medical University Cancer Institute and Hospital from January 2003 to January 2004 were studied and followed up until May 2011. Serum levels of biochemical markers for tumor and liver were measured at the time of diagnosis. RESULTS: Liver metastasis was more likely to occur in patients with stage III cancer or c-erbB-2-positive expression. Alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase (GGT), alkaline phosphatase, lactate dehydrogenase (LDH), and carbohydrate antigen 153 (CA153) levels were significantly higher in patients with liver metastasis than those without liver metastasis. Diagnostic indices of LDH, GGT, and CA153 were 174 U/L, 32 U/L, and 26.48 µg/L, respectively. The areas under the curves of LDH, GGT, and CEA were 0.795, 0.784, and 0.661, respectively, and sensitivities of parallel tests for LDH and CA153 and for GGT and CA153 were 88.6% and 85.7%, respectively. The specificity of serial tests for both pairs of enzymes was 97.7%. CONCLUSIONS: The sensitivity and specificity of combined tumor and biochemical markers could be used as indicators during screening for breast-liver metastasis. Chinese Anti-Cancer Association 2012-03 /pmc/articles/PMC3643646/ /pubmed/23691457 http://dx.doi.org/10.3969/j.issn.2095-3941.2012.01.011 Text en 2012 Cancer Biology & Medicine This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/
spellingShingle Original Article
Cao, Rui
Wang, Li-ping
Serological Diagnosis of Liver Metastasis in Patients with Breast Cancer
title Serological Diagnosis of Liver Metastasis in Patients with Breast Cancer
title_full Serological Diagnosis of Liver Metastasis in Patients with Breast Cancer
title_fullStr Serological Diagnosis of Liver Metastasis in Patients with Breast Cancer
title_full_unstemmed Serological Diagnosis of Liver Metastasis in Patients with Breast Cancer
title_short Serological Diagnosis of Liver Metastasis in Patients with Breast Cancer
title_sort serological diagnosis of liver metastasis in patients with breast cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643646/
https://www.ncbi.nlm.nih.gov/pubmed/23691457
http://dx.doi.org/10.3969/j.issn.2095-3941.2012.01.011
work_keys_str_mv AT caorui serologicaldiagnosisoflivermetastasisinpatientswithbreastcancer
AT wangliping serologicaldiagnosisoflivermetastasisinpatientswithbreastcancer